Top

Journal of Endocrinological Investigation

Published in:

01-04-2014 | Original Article

Protective effects of pioglitazone against immunoglobulin deposition on heart of streptozotocin-induced diabetic rats

Authors: M. Yuan, M. Qiu, J. Cui, X. Zhang, P. Zhang

Published in: Journal of Endocrinological Investigation | Issue 4/2014

Abstract

Aim

Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have immunomodulatory and anti-inflammatory effects. The study investigated the autoimmune injuries of diabetic cardiomyopathy (DCM) and tested the hypothesis that PPAR-γ agonists suppress disordered immune responses in diabetic heart, thereby preventing evolution of DCM.

Methods

STZ-induced diabetic rats were assigned to five groups: DM group, given no treatment; INS group, given insulin (4U kg⁻¹ d⁻¹); PIL group, given low dose pioglitazone (4 mg kg⁻¹ d⁻¹); PIL/INS group, given both low dose pioglitazone and insulin; PIH group, given high dose pioglitazone (20 mg kg⁻¹ d⁻¹). Normal rats (CON group) were also monitored as control. The pathologic abnormalities of hearts were observed. The immunoglobulin deposition was examined by immunohistochemistry and immunofluorescence.

Results

At 16 weeks, interstitial fibrosis was shown in diabetic heart which was accompanied by plenty of inflammatory cells infiltrated. Pioglitazone therapy could ameliorate the cardiac injuries. Shown by immunohistochemistry, the difference of integrated optical density (IOD) of immunoglobulin deposition among each group had statistic significance. No obvious immunoglobulins were deposited in the intercellular substance of heart in CON group (IgA 290.8 ± 88.1, IgG 960.4 ± 316.0 and IgM 341.3 ± 67.9). But the deposition of immunoglobulins increased significantly in DM group (IgA 7,047.5 ± 1,328.3, P < 0.05; IgG 28,945.9 ± 5,160.7, P < 0.05 and IgM 8,580.8 ± 1,336.8, P < 0.05). Administration of pioglitazone greatly reduced the increased deposition in a dose-dependent fashion. Moreover, the statistical significance was the same with immunofluorescence analysis as with immunohistochemical examination.

Conclusions

The data suggest that disordered immune responses play an important role in the pathogenesis of DCM. Pioglitazone showed protective effects by inhibiting the immunoglobulin deposition on diabetic myocardium.

Gao H, Qiu M (2005) More research work should be done on the pathogenesis of autoimmune injuries to the multiple organs in some T2 diabetes Mellitus. Natl Med J China 85:793–795

Qiu M, Meng C (2006) The role of complement activation in the pathogenesis of diabetic complications. Chin J Endocrinol Metab 22:303–305

Meng C, Gao H, Qiu M et al (2006) Immunological injury on the retina in streptozotocin-induced diabetic rats. Chin J Endocrinol Metab 22:588–589

Zhang X, Cui J, Qiu M et al (2008) The effects of cyclosporine A on immunoglobulins deposition in retina of streptozotocin-induced diabetic rats. Chin J Intern Med 47:125–128

Cui J, Zhang P, Qiu M et al (2010) Preventive effects of cyclosporine A on immunoglobulins deposition on heart of STZ-induced diabetic rats. Chin J Diabetes Mellitus 2:142–147

Cui J, Qiu M, Li D et al (2010) The protective effects of cyclosporine A on aortic immunological injuries in STZ-induced diabetic rats. Chin J Cardiol 38:440–444

Pershadsingh HA (2004) Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 13:215–228PubMedCrossRef

Lena S, Samir NP, Kodjo A et al (2009) Rosiglitazone modulates innate immune responses to Plasmodium falciparum and improves outcome in experimental cerebral malaria. J Infect Dis 199:1536–1545CrossRef

Cuzzocrea S, Pisano B, Dugo L et al (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483:79–93PubMedCrossRef

10.

Antonelli A, Ferrari SM, Frascerra S et al (2010) CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves’ and normal thyrocytes. J Clin Endocrinol Metab 95:E413–E420PubMedCrossRef

11.

Klotz L, Schmidt M, Giese T et al (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175:4948–4955PubMedCrossRef

12.

Von Knethen A, Brune B (2002) Activation of peroxisome proliferator activated receptor γ by nitric oxide in monocytes/macrophages down-regulates p47^phox and attenuates the respiratory burst. J Immunol 169:2619–2626CrossRef

13.

Faine LA, Rudnicki M, César FA et al (2011) Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages. Curr Med Chem 18:3351–3360PubMedCrossRef

14.

Choi JM, Bothwell AL (2012) The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells 33:217–222PubMedCentralPubMedCrossRef

15.

Cunard R, Eto Y, Muljadi JT et al (2004) Repression of IFN-γ expression by peroxisome proliferator-activated receptor γ. J Immunol 172:7530–7536PubMedCrossRef

16.

Housley WJ, Adams CO, Vang AG et al (2011) Peroxisome proliferator-activated receptor gamma is required for CD4 + T cell-mediated lymphopenia-associated autoimmunity. J Immunol 187:4161–4169PubMedCentralPubMedCrossRef

17.

Yanagita M, Kobayashi R, Kojima Y et al (2012) Nicotine modulates the immunological function of dendritic cells through peroxisome proliferator-activated receptor-γ upregulation. Cell Immunol 274:26–33PubMedCrossRef

18.

Niino M (2007) Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis. Mini Rev Med Chem 7:1129–1135PubMedCrossRef

19.

Peiris M, Monteith GR, Roberts-Thomson SJ et al (2007) A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies. J Neurosci Methods 163:245–254PubMedCrossRef

20.

Hasegawa H, Takano H, Zou Y et al (2005) Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. J Mol Cell Cardiol 38:257–265PubMedCrossRef

21.

Yuan Z, Liu Y, Zhang J et al (2005) Cardioprotective effects of peroxisome proliferator activated receptor c activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor κB blockade. Heart 91:1203–1208PubMedCentralPubMedCrossRef

22.

Demerjian M, Man MQ, Choi EH et al (2006) Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 15:154–160PubMedCrossRef

23.

Pershadsingh HA, Benson SC, Ellis CN (2005) Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skin med 4:386–390CrossRef

24.

Schaefer KL, Denevich S, Ma C et al (2005) Intestinal antiinflammatory effects of thiazolidinedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 11:244–252PubMedCrossRef

25.

Buckingham RE (2005) Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol Res 33:167–170PubMedCrossRef

26.

Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813–823PubMedCrossRef

27.

Donath MY, Storling J, Maedler K et al (2003) Inflammatory mediators and islet beta-cell failure. A link between type 1 and type 2 diabetes. J Mol Med 81:455–470PubMedCrossRef

28.

Gale EAM (2006) Declassifying diabetes. Diabetologia 49:1989–1995PubMedCrossRef

29.

Kurien BT, Scofield RH (2008) Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 7:567–573PubMedCentralPubMedCrossRef

30.

Kurien BT, Hensley K, Bachmann M et al (2006) Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 41:549–556PubMedCrossRef

31.

Ahmed N, Babaei-Jadidi R, Howell SK et al (2005) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590–1603PubMedCrossRef

32.

Wang G, Li H, Firoze Khan M (2012) Differential oxidative modification of proteins in MRL+/+ and MRL/lpr mice: increased formation of lipid peroxidation-derived aldehyde-protein adducts may contribute to accelerated onset of autoimmune response. Free Radic Res 46:1472–1481PubMedCrossRef

33.

Tam LS, Shang Q, Li EK et al (2013) Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis-a prospective study. Semin Arthritis Rheum 42:333–345PubMedCrossRef

34.

Speidl WS, Kastl SP, Huber K et al (2011) Complement in atherosclerosis: friend or foe? J Thromb Haemost 9:428–440PubMedCrossRef

35.

Fosbrink M, Niculescu F, Rus V et al (2006) C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 281:19009–19018PubMedCrossRef

36.

Raquel H, William TH, Montse C et al (2011) Immunoregulatory mechanisms of macrophage PPAR γ in mice with experimental inflammatory bowel disease. Mucosal Immunol 4:304–313CrossRef

37.

Zhang W, Eric AS, Paska AP et al (2008) Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol 28:2312–2318PubMedCrossRef

38.

Gao M, Hu Z, Zheng Y et al (2011) Peroxisome proliferator-activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1. Shock 36:228–234PubMedCrossRef

39.

Chen J, Mehta JL (2006) Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291:H1738–H1745PubMedCrossRef

40.

Ti Y, Hao MX, Li CB et al (2011) Rosiglitazone attenuates myocardial remodeling in spontaneously hypertensive rats. Hypertens Res 34:354–360PubMedCrossRef

41.

Straus DS, Glass CK (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28:551–558PubMedCrossRef

42.

Chawla A, Barak Y, Nagy L et al (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48–52PubMedCrossRef

43.

Lee JH, Woo JH, Woo SU et al (2008) The 15-deoxy-delta 12,14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1. J Immunol 181:8642–8649PubMedCrossRef

44.

Asakawa M, Takano H, Nagai T et al (2002) Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240–1246PubMedCrossRef

45.

Tsuji T, Mizushige K, Noma T et al (2001) Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 38:868–874PubMedCrossRef

46.

Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A (2002) Rosiglitazone, a peroxisome proliferator-activated receptorgamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51:1507–1514PubMedCrossRef

47.

Liu HR, Tao L, Gao E et al (2004) Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135–144PubMedCrossRef

48.

Dormandy JA, Charbonnel B, Eckland DJA et al (2005) PRO active investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone clinical trial in macro vascular events): a randomised controlled trial. Lancet 366:1279–1289PubMedCrossRef

49.

Derosa G (2010) Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 70:1945–1961PubMedCrossRef

Title: Protective effects of pioglitazone against immunoglobulin deposition on heart of streptozotocin-induced diabetic rats
Authors: M. Yuan
M. Qiu
J. Cui
X. Zhang
P. Zhang
Publication date: 01-04-2014
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 4/2014
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-013-0046-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2014

Clinical study of exercise on improvement of β-cell function and insulin resistance in non-diabetic young offsprings of diabetic patients

Increased amino acids levels and the risk of developing of hypertriglyceridemia in a 7-year follow-up

Impact of overweight and obesity on obstetric outcomes

Normative reference of short-term heart rate variability and estimation of cardiovascular autonomic neuropathy prevalence in Chinese people

Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking

The effect of steroid pulse therapy on carbohydrate metabolism in multiple myeloma patients: a randomized crossover observational clinical study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials